FY2025 · ended Dec 31, 2025 · Revenue $32.03M, +17.4% YoY · Filed Mar 16, 2026
Zomedica Corp. (ZOMDF) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $32.0 million and a net loss of $81.9 million. Free cash flow was -$18.2 million. As of Sep 30, 2026 it held $7.3 million in cash and investments and $1.6 million in total debt.
Revenue (TTM)
$38.68M
+31.3% vs year-ago TTM
Net income (TTM)
$-15.99M
+81.1% vs year-ago TTM
Operating cash flow (TTM)
$-11.48M
+46.1% vs year-ago TTM
Free cash flow (TTM)
$-11.92M
+46.6% vs year-ago TTM
EPS
$-0.08
-60.0% vs prior year
Dividend per share
None
Shares outstanding
979.95M
+0.0% vs prior year
Net cash
$5.63M
as of Sep 30, 2026
Operating margin
-45.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZOMDF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Alberta, Canada
- Headquarters
- Ann Arbor, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1684144
- Former names
- Zomedica Pharmaceuticals Corp. (until Sep 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2022 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $32.0M | $27.3M | $25.2M | $18.9M | $4.1M |
| Operating income | -$84.4M | -$51.1M | -$43.3M | -$21.9M | -$21.4M |
| Net income | -$81.9M | -$47.0M | -$34.5M | -$17.0M | -$18.4M |
| Diluted EPS | -$0.08 | -$0.05 | -$0.04 | — | — |
| Operating cash flow | -$17.6M | -$23.6M | -$16.0M | -$11.7M | -$14.3M |
| Free cash flow | -$18.2M | -$28.8M | -$27.3M | -$12.5M | -$14.4M |
| Total assets | $127.0M | $207.4M | $253.2M | $279.6M | $280.4M |
| Total liabilities | $11.6M | $11.7M | $13.2M | $12.2M | $9.5M |
| Stockholders' equity | $115.4M | $195.7M | $240.0M | $267.4M | $270.9M |
| Cash and investments | $9.0M | $7.0M | $13.0M | $27.4M | $195.0M |
| Total debt | $2.2M | $1.8M | $2.7M | $1.7M | $1.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
All 482 Zomedica Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.